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ABSTRACT
We reviewed the clinical outcome of 8 patients with steroid-refractory chronic graft-versus-host disease (GVHD)
who received an anti-CD20 chimeric monoclonal antibody (rituximab). Rituximab was given by intravenous
infusion at a weekly dose of 375 mg/m2 for 4 weeks. All patients had received extensive treatment with various
immunosuppressive agents; 6 patients had also received extracorporeal photopheresis. All patients had extensive
chronic GVHD with diffuse or localized sclerodermoid GVHD and xerophthalmia. Other extracutaneous involve-
ments included cold agglutinin disease with the Raynaud phenomenon, membranous glomerulonephritis, and
restrictive or obstructive lung disease. Four patients responded to treatment with ongoing resolution or improve-
ment ranging from 265 to 846 days after therapy, despite recovery of B cells in 3 patients. Rituximab seems to have
significant activity in the treatment of refractory chronic GVHD and should be considered for further study in
patients with early disease. This study suggests a participating role of B cells in the pathogenesis of chronic GVHD.
© 2003 American Society for Blood and Marrow Transplantation
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PNTRODUCTION
Chronic graft-versus-host disease (GVHD) re-
ains a formidable complication for long-term survi-
ors of hematopoietic stem cell transplantation. The
rimary treatment of chronic GVHD has mainly re-
ied on systemic corticosteroids. The addition of other
mmunosuppressive agents to corticosteroids has not
esulted in improvement of efﬁcacy [1,2]. Various
gents have been studied for salvage therapy in the
etting of corticosteroid failure, with some reported
uccess [3]. However, the protean manifestations of
hronic GVHD could confound the ability to accu-
ately assess the efﬁcacy of these agents, especially
hen they are used as salvage therapy.
Conventional opinions regarding organ rejection,
VHD, and transplantation tolerance have centered on
primary role for T cells in mediating immunologic
ttacks on the target tissues [4]. However, there is evi-
ence of B-cell dysregulation that might contribute to
he pathogenesis of chronic GVHD. In a case report, t
B&MThrombocytopenia associated with chronic GVHD was
uccessfully treated with B-cell depletion by using an
nti-CD20 monoclonal antibody (rituximab [Rituxan];
DEC Pharmaceuticals Corp., San Diego, CA) [5].
ther clinical manifestations of chronic GVHD in this
atient, including oral lichen planus, skin, and xeroph-
halmia, also became quiescent after rituximab use, al-
owing gradual discontinuation of immunosuppressants.
ormalization of thrombocytopenia in this patient was
urable despite B-cell recovery, suggesting that toler-
nce may be induced with B-cell depletion.
In this article, we report a retrospective case series
f 8 patients with refractory chronic GVHD treated
ith rituximab. The clinical responses observed in this
rticle suggest a role of B-cell depletion in treating
ome manifestations of chronic GVHD.
ATIENTS AND METHODS
From September 2000 to October 2002, wetransplantation Hematopoietic stem cell t
oi:10.1016/S1083-8791(03)00216-7ntation Anti-CD20 antibody B-cell depletionranspla
t
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dreated 8 adults who had undergone an allogeneic
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sibling stem cell transplantation for hematologic ma-
lignancies and who had refractory chronic GVHD
treated with rituximab. The dose of rituximab was 375
mg/m2 given intravenously weekly for 4 weeks. The
initial rate of infusion was 50 mg/h. If there was no
reaction to the infusion, the rate was increased by 50
mg/h increments every 30 minutes to a maximum of
400 mg/h. All patients were premedicated with acet-
aminophen 650 mg and diphenhydramine 50 mg
orally. We retrospectively reviewed the clinical data
and outcome of these 8 patients. This study was ap-
proved by the institutional review board.
RESULTS
All patients had extensive chronic GVHD with
sclerodermoid involvement of skin/soft tissues and
xerophthalmia. One other patient had limited sclero-
dermoid involvement of the lateral thoracic cage and
abdominal wall but developed painful ischemic ﬁngers
on both hands because of cold agglutinins and the
Raynaud phenomenon. All but 1 patient had progres-
sive onset of chronic GVHD.
Prior treatment for chronic GVHD included ta-
crolimus and methylprednisolone for all patients.
Seven patients were taking at least 3 immunosuppres-
sive agents before or during rituximab therapy. Six
patients had received extracorporeal photopheresis
(ECP) before rituximab, without response. With the
exception of case 4, no patient received methylpred-
nisolone or hydrocortisone during rituximab infusion.
Patients who responded to rituximab had their immu-
nosuppression tapered gradually. For nonresponders,
the dose of immunosuppression was increased or ad-
ditional agents were added as clinically indicated.
The median age of the patients was 46 years
(range, 28-58 years). The median time from trans-
plantation to rituximab was 18 months (range, 13-90
months); the median duration of follow-up after rit-
uximab was 265 days (range, 104-846 days).
Patient demographics, prior therapy of chronic
GVHD, and response to therapy are summarized in
Table 1. A clinical response to rituximab was noted in
4 of 8 patients, as detailed below.
Case 1
A 31-year-old woman developed progressive
chronic GVHD that was unresponsive to tacrolimus,
methylprednisolone, mycophenolate, hydroxychloro-
quine, thalidomide, acitretin, and ECP. The predom-
inant clinical feature was generalized sclerodermoid
chronic GVHD interspersed with ulcerating lichen
planus. The most disabling sclerodermoid GVHD
involved the anterior cervical fascia, resulting in a
severe ﬂexion contracture (Figure 1). After rituximab
therapy, her immunosuppressive agents were able to
be tapered gradually over 7 months, with improve-
ment of skin GVHD. The range of motion of her neck
had improved to near normal 1 year after treatment
with rituximab (Figure 2). The dose of immunosup-
pression was tapered from tacrolimus 1.5 mg twice
daily (BID) and methylprednisolone 32 mg daily at the
initiation of rituximab to tacrolimus 0.5 mg daily and
methylprednisolone 4 mg daily at the last follow-up
visit.
Case 2
A 38-year-old man had biopsy-proven liver
GVHD (lobular hepatitis with mild bile duct damage
compatible with GVHD) at day 60 after transplanta-
tion. He was treated with methylprednisolone and
tacrolimus, with complete resolution of his liver dis-
ease. Eleven months after transplantation, he devel-
oped painful ischemic ﬁngers consistent with the
Raynaud phenomenon and was treated with nifedi-
pine, without relief. He also had other signs and
symptoms of chronic GVHD involving the eyes and
mouth and limited sclerodermoid and fasciitis changes
of the lower thoracic cage and abdomen. His ﬁnger-
tips had bluish discoloration and were very painful to
touch and movement. He had a cold agglutinin titer of
1:40 and an absence of cryoglobulin. He was started
on 2 mg/kg/d of methylprednisolone, which was re-
duced several weeks later because of a lack of improve-
ment and steroid intolerance (Figure 3). Despite cor-
ticosteroids, ischemic changes of the ﬁngertips
became more pronounced, and early necrosis of his
ﬁngertips appeared. He was then started on rituximab.
Three months after treatment with rituximab, his ﬁn-
gers returned to normal, without pain, despite the
continuing taper of methylprednisolone (Figure 4).
Cold agglutinins were not detectable after rituximab
therapy was completed. Other manifestations of
chronic GVHD involving the eyes, mouth, and soft
tissue also improved, allowing methylprednisolone to
be tapered from 32 mg BID to 10 mg daily.
Case 3
A 48-year-old man with advanced immunoglobu-
lin G myeloma developed a clinical grade 3 acute
GVHD involving the skin and gastrointestinal tract
early in the course of transplantation. His acute
GVHD responded to methylprednisolone and tacroli-
mus, but at 1 year after transplantation, he was noted
to have xerophthalmia, xerostomia, and eosinophilia.
At the same time, because of concern for progression
of his myeloma (indicated by an increasing M spike),
his immunosuppression was gradually tapered. Several
weeks later, he developed nephrotic syndrome, with
proteinuria of 20 g/24 hours, and the renal biopsy
showed membranous glomerulonephritis. There was
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no light chain proteinuria and no detectable mono-
clonal spike on serum protein electrophoresis. He
initially responded to increasing immunosuppression
with methylprednisolone and the addition of myco-
phenolate. Over the ensuing 3 months, his proteinuria
improved and plateaued at 13 to 14 g/24 hours,
whereas his creatinine clearance declined, and tacroli-
mus was replaced with sirolimus. His skin also showed
mottled sclerodermoid changes, particularly over the
distal extremities and lateral torso; his xerophthalmia
was increasingly symptomatic. Five months after the
diagnosis of membranous glomerulonephritis, his pro-
teinuria remained unchanged, and rituximab was ini-
tiated. Both his proteinuria and other manifestations
of chronic GVHD gradually improved despite the
tapering of immunosuppressants (Figure 5). Nine
months after rituximab, a 24-hour urinary protein was
measured at 4 g. His renal function and proteinuria
Table 1. Patient Demographics, Prior Therapy, Response, and Status
Case
No.
Age/
Sex Diagnosis
Preparative
Regimen
Source
of Stem
Cells
Type of
Onset
Organ
Involvement Prior Therapy
Interval from
Transplantation
to Rituximab
Therapy (mo) Response Status
1 31/F T/NK NHL CVB PB/Sis Progressive Extensive
sclerodermoid;
lichen planus;
eyes; chronic
bronchitis;
cervical flexion
contracture
Tacrolimus, MP, MMF,
hydroxychloroquine,
infliximab,
thalidomide,
acitretin, ECP
13 Responded Alive at 42 mo
after
transplantation
continuing
response at
868 d
2 38/M CML/AP BAC PB/Sis Progressive Localized
sclerodermoid
involvement of
the skin and soft
tissue, eyes, and
liver; cold
agglutinin and
Raynaud
phenomenon
Tacrolimus, MP 13 Responded Alive at 27 mo
after
transplantation
continuing
response at
369 d
3 48/M Myeloma BuCyTMI PB/Bro Progressive Extensive
sclerodermoid;
eyes, kidney
Tacrolimus, MP, MMF 14 Responded Alive at 29 mo
after
transplantation
continuing
response at
294 d
4 46/M MDS BAC BM/Sis Progressive Extensive
sclerodermoid
interspersed with
lichen planus,
eyes, liver;
restrictive/obstructive
lung disease
Tacrolimus, CSA, MP,
azathioprine, MMF,
ECP
90 Responded Alive at 99 mo
after
transplantation
continuing
response at
265 d
5 58/M MCL RI PB/Sis Progressive Extensive
sclerodermoid,
eyes
Tacrolimus, MP, MMF,
hydroxychloroquine,
ECP
19 NR Alive at 27 mo
after
transplantation
6 41/F CML BuCy-2 PB/Sis De novo Extensive
sclerodermoid;
lichen planus;
eyes; chronic
bronchitis
Tacrolimus, MP, MMF,
hydroxychloroquine,
thalidomide,
acitretin, ECP
49 NR Alive at 55 mo
after
transplantation
7 48/M MDS BAC PB/Sis Progressive Extensive
sclerodermoid;
eyes
Tacrolimus, MP, MMF,
ECP
33 NR Alive at 39 mo
after
transplantation
8 28/M ALL CY/TBI PB/Bro Progressive Extensive
sclerodermoid;
eyes
Tacrolimus, MP, MMF,
hydroxychloroquine,
ECP
40 NR Alive at 45 mo
after
transplantation
MP indicates methylprednisolone; MMF, mycophenolate mofetil; ECP, extracorporeal photopheresis; MDS, myelodysplastic syndrome;
CY, cyclophosphamide 60 mg/kg intravenously daily for 2 days; TBI, total body irradiation 2 Gy twice a day on 3 consecutive days; ALL, acute
lymphocytic leukemia; AML, acute myeloid leukemia; CML, chronic myeloid leukemia; MCL, mantle cell lymphoma; BM, bone marrow; PB,
peripheral blood; BAC, 3 agents given consecutively (busulfan 1 mg/kg every 6 hours orally for 16 doses, cytarabine 2 g/m2 every 12 hours
for 4 doses, and cyclophosphamide 60 mg/kg daily for 2 days); BuCy-2, busulfan 1 mg/kg every 6 hours orally for 16 doses and
cyclophosphamide 60 mg/kg daily for 2 days; RI, reduced-intensity regimen of ﬂudarabine 25 mg/m2 intravenously daily for 5 days (days 11
to 7) followed by busulfan 0.5 mg/kg orally every 6 hours for 16 doses (days 6 to 3), MMF 750 mg orally twice per day for actual weight
80 kg and 1000 mg orally twice per day for weight80 kg from day6 to day 0, and total lymphoid irradiation of 2 Gy on day 0; BuCyTMI,
sequential busulfan 0.875 mg/kg orally every 6 hours for 16 doses, cyclophosphamide 60 mg/kg intravenously daily for 2 days, and total marrow
irradiation to a total dose of 8.5 Gy; M, male; F, female; bro, brother; sis, sister; NR, no response; CSA, cyclosporine; CVB, regimen of
cyclophosphamide 1800 mg/m2 intravenously on day7 to4, etoposide 200 mg/m2 intravenously q12h on day7 to4, BCNU 450 mg/m2
intravenously on day 3; AP, accelerated phase.
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continued to improve despite the reduction of immu-
nosuppression. At the last follow-up visit, he was tak-
ing methylprednisolone 8 mg every other day and
sirolimus 1 mg daily.
Case 4
A 49-year-old man who had received allogeneic
marrow stem cell transplantation developed progres-
sive-onset chronic GVHD. The prominent feature
was slowly progressive sclerodermoid skin changes
over the entire torso, limiting chest wall compliance
and resulting in severe restrictive lung disease. Pul-
monary function studies also indicated obstructive
physiology. Seven years after transplantation, ECP
was initiated. After 5 months of ECP therapy, there
was minimal softening of the skin of both lower distal
extremities but no signiﬁcant improvement of his re-
spiratory dysfunction. Ninety months after transplan-
tation, with increasing oxygen requirements, the pa-
tient was given rituximab. He experienced severe
respiratory difﬁculty with the ﬁrst rituximab infusion
and required a single intravenous dose of methylpred-
nisolone 40 mg and aerosolized albuterol. The subse-
quent 3 doses of rituximab were given without further
difﬁculty after premedication with hydrocortisone 100
Figure 1. This patient (case 1) showed cervical ﬂexion contracture
(caused by dense ﬁbrosis of the anterior cervical fascia), blotchy
hyperpigmentation, hidebound facial skin, and circumoral stricture.
Figure 2. Resolution of the cervical ﬂexion contracture and im-
provement of the sclerodermoid changes of the facial skin.
Figure 3. Painful cyanotic ﬁngers in a patient (case 2) with cold
agglutinin.
Figure 4. Resolution of painful cyanotic ﬁngers after antibody
therapy.
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mg intravenously. Two weeks after he completed a
course of rituximab, his lung capacity had improved
sufﬁciently to become oxygen independent, and he
was able to participate in household chores. His forced
vital capacity and forced expiratory volume in 1 sec-
ond improved from 28% and 33% before rituximab
therapy to 57% and 63%, respectively, after rituximab
therapy. Serial pulmonary function studies and treat-
ments given are summarized in Figure 6. The patient
was maintained on tacrolimus 1 mg BID and myco-
phenolate 1 g BID.
Cases 5 to 8
Four patients did not respond to rituximab ther-
apy. Three of 4 patients had a rapid onset of diffuse
inﬂammatory changes of the skin associated with
edema of both upper extremities. The involved skin
was tender to pressure, and there was a limited range
of motion of the involved extremities. The inﬂamma-
tory changes were most pronounced over the distal
extremities. Fibrosis and postinﬂammatory hyperpig-
mentation of the skin ensued within 8 weeks of onset.
Progressive ﬁbrosis later involved the lower lateral
thoracic cage, with restricted respiratory movement.
One patient (case 6) had slowly progressive ﬁbrosis of
the distal upper extremities associated with lichen pla-
nus clustering over the wrists, palmar surfaces, and
shoulders, with scattered lesions on the trunk and
axillary folds. Patchy areas of dense ﬁbrosis were lim-
ited to the volar surfaces of the forearms, axillary folds,
and scattered lesions over the neck. There was severe
pain and tenderness of the ulcerating lesions of lichen
planus.
DISCUSSION
In our initial observation in a patient with chronic
GVHD-associated thrombocytopenia, there was a
dramatic response of her thrombocytopenia to treat-
ment with rituximab [5]. Furthermore, other clinical
manifestations of chronic GVHD, eg, skin involve-
ment and dry eyes, also improved despite discontinu-
ation of immunosuppressive therapy. This observation
suggested that other organ manifestations of chronic
GVHD may also respond to B-cell depletion.
The role of B cells in the pathogenesis of autoim-
mune disorders is a subject of debate. There is mount-
ing evidence that hyperactivity of B cells may be the
deﬁning event in systemic lupus erythematosus, lead-
ing to production of pathogenic autoantibodies that
results in end-organ damage [6]. Similarly, in a murine
model of chronic GVHD, parent into F1 model
(C57BL/6  DBA2), the expansion of host B cells in
response to donor CD4 was thought to play a central
role in the development of chronic GVHD with au-
toantibody production and glomerulonephritis [7,8].
It is uncertain whether this nonradiation model of
GVHD bears any relevance to the human GVHD,
because until recently most preparative regimens used
in clinical stem cell transplantation were myeloabla-
tive. However, the clinical resemblance of this murine
model to chronic GVHD in humans with autoanti-
body production would suggest the pathogenetic role
of B cells in some of the manifestations of this syn-
drome.
Recently, depletion of B cells by using rituximab
[9] has shown efﬁcacy in the treatment of several
autoimmune disorders [10], including chronic idio-
pathic thrombocytopenia [11], autoimmune polyneu-
ropathy [12], autoimmune hemolytic anemia [13],
cold agglutinin disease [14], pure red cell aplasia [15],
Wegener granulomatosis [16], idiopathic membra-
nous nephropathy [17], and rheumatoid arthritis [18].
Rituximab has also been shown to be effective in the
treatment of various immune-mediated complications
related to chronic GVHD or allogeneic transplanta-
tion, eg, thrombocytopenia [5], myasthenia gravis
[19], and autoimmune hemolytic anemia [20]. It is
interesting to note that other manifestations of
chronic GVHD were also noted to be responding to
Figure 5. Response of proteinuria in a patient with membranous
glomerulonephritis.
Figure 6. Response of restrictive or obstructive pulmonary physi-
ology to antibody therapy; (f) forced vital capacity, () forced
expiratory volume in 1 second.
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this treatment in some patients. Furthermore, the re-
sponse seemed to be durable despite recovery of B
cells, suggesting that tolerance may be achieved with
this therapy.
Numerous treatment strategies for chronic
GVHD with varying degrees of success have been
reported [5,21-23]. Among the treatments studied,
ECP is by far the most effective, with 38% to 80%
complete resolution of skin involvement, 48% to 70%
improvement of liver involvement, and 39% improve-
ment of lung involvement [24,25]. In our series, 6
patients had received prior ECP therapy, and only 2 of
these patients responded. It is not likely that prior
ECP affected the outcome of rituximab therapy. Of
the 4 patients who responded to rituximab therapy, 2
patients had predominantly skin and soft tissue in-
volvement (sclerodermoid chronic GVHD and lichen
planus). The remaining 2 patients had membranous
glomerulonephritis and Raynaud phenomenon related
to cold agglutinins. The temporal relationship of cold
agglutinin disease and glomerulonephritis with the
ongoing activity of chronic GVHD in our patients
suggested that the immunopathogenesis of these
chronic GVHD manifestations might be similar to
that in patients with autoimmune diseases. Objective
responses to rituximab included disappearance of cold
agglutinin titers and resolution of the Raynaud phe-
nomenon (case 2), decline in urinary protein excretion
(case 3), and improvement of sclerodermatous changes
of the thoracic cage with a marked improvement in
the pulmonary spirogram (case 4). The remaining
patient (case 1) had resolution of the severe cervical
ﬂexion contracture from diffuse scleroderma and heal-
ing of the ulcerating lichen planus. The time to clin-
ical and laboratory improvement ranged from 1
month in a patient (case 2) with cold agglutinin disease
to 4 months in a patient with diffuse scleroderma and
lichen planus.
In patients with membranous glomerulonephritis
and cold agglutinin disease, the presence of autoanti-
body may be implicated as the cause of the unique
manifestations of chronic GVHD. Depletion of
CD20 B cells, the potential precursors of the autoan-
tibody-producing cells, might explain the efﬁcacy of
rituximab in treatment of autoimmune manifestations.
However, depletion of B cells alone may not be the
only mechanism responsible for rapid recovery from
thrombocytopenia [5,11]. Fc receptor blockade by op-
sonized B cells may also play a role in rapid clinical
improvement [26]. Similar mechanisms involving de-
pletion of autoantibody-producing B cells might be
operating in patients with sclerodermoid chronic
GVHD and patients with systemic sclerosis and re-
lated ﬁbrosing disorders [27]. Furthermore, higher
levels of B-cell activation in the granulocyte colony-
stimulating factor mobilized peripheral blood stem
cell may be an important contributing factor in the
increased incidence of chronic GVHD in recipients of
allogeneic stem cell transplants [28].
The role of T cells in mediating endothelial injury
in patients with chronic GVHD has also been de-
scribed. Compromised tissue perfusion resulting from
endothelialitis eventually leads to tissue hypoxia and
ﬁbrosis, which is the hallmark of chronic GVHD
pathology [29]. It is unclear how T and B cells interact
to sustain the immunologic assaults on target tissues.
One of the mechanisms might involve antigen presen-
tation by interaction of dendritic cells with B cells,
leading to generation of peptide/major histocompati-
bility complex complexes by B cells that then pre-
sented to T cells [30,31]. A clinical example of the
collaboration of T and B cells in chronic GVHD-
associated bullous pemphigoid was recently reported
[32]. Furthermore, Miklos et al. [33] have demon-
strated B-cell responses to DBY (a minor H-Y minor
histocompatibility antigen) in 48% of male recipients
from female grafts, indicating the collaboration of T
and B cells to produce speciﬁc antibodies against host
antigens.
Four patients in this series did not respond to
B-cell depletion. Serial peripheral blood CD19 cell
counts obtained in 4 patients (3 responders and 1
nonresponder) demonstrated no detectable CD19
cells after rituximab therapy (data not shown). It is
possible that some autoantibody-producing cells or
their precursors were not depleted because of the
absence or low expression of CD20. Other mecha-
nisms of antigen presentation not involving B cells
might also be dominant in sustaining the dysregulated
immune response. In these situations, treatment with
rituximab, a highly effective agent for B-cell deple-
tion, would not be sufﬁcient in eliminating pathogenic
autoantibodies.
The efﬁcacy of rituximab in patients with chronic
GVHD demonstrated in this retrospective study sug-
gests a pathogenetic role of B cells in this disease.
Depletion of B cells with rituximab resulted in clinical
and laboratory improvement of chronic GVHD in 4
of 8 patients with refractory chronic GVHD. Sus-
tained improvement of clinical signs and symptoms of
chronic GVHD, despite B-cell recovery, may indicate
that the induction of tolerance may have occurred.
This novel therapy should be tested in a prospective
study in patients with earlier stages of chronic
GVHD.
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